TNFα inhibitors as targets for protective therapies in MSA: a viewpoint

Multiple system atrophy (MSA) is a unique and fatal α-synucleinopathy associated with oligodendroglial inclusions and secondary neurodegeneration affecting striatum, substantia nigra, pons, and cerebellum. The pathogenesis remains elusive; however, there is emerging evidence suggesting a prominent r...

Descripción completa

Detalles Bibliográficos
Autores principales: Ndayisaba, Alain, Jellinger, Kurt, Berger, Thomas, Wenning, Gregor K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458780/
https://www.ncbi.nlm.nih.gov/pubmed/30975183
http://dx.doi.org/10.1186/s12974-019-1477-5
_version_ 1783410081421852672
author Ndayisaba, Alain
Jellinger, Kurt
Berger, Thomas
Wenning, Gregor K.
author_facet Ndayisaba, Alain
Jellinger, Kurt
Berger, Thomas
Wenning, Gregor K.
author_sort Ndayisaba, Alain
collection PubMed
description Multiple system atrophy (MSA) is a unique and fatal α-synucleinopathy associated with oligodendroglial inclusions and secondary neurodegeneration affecting striatum, substantia nigra, pons, and cerebellum. The pathogenesis remains elusive; however, there is emerging evidence suggesting a prominent role of neuroinflammation. Here, we critically review the relationship between αS and microglial activation depending on its aggregation state and its role in neuroinflammation to explore the potential of TNFα inhibitors as a treatment strategy for MSA and other neurodegenerative diseases.
format Online
Article
Text
id pubmed-6458780
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64587802019-04-22 TNFα inhibitors as targets for protective therapies in MSA: a viewpoint Ndayisaba, Alain Jellinger, Kurt Berger, Thomas Wenning, Gregor K. J Neuroinflammation Review Multiple system atrophy (MSA) is a unique and fatal α-synucleinopathy associated with oligodendroglial inclusions and secondary neurodegeneration affecting striatum, substantia nigra, pons, and cerebellum. The pathogenesis remains elusive; however, there is emerging evidence suggesting a prominent role of neuroinflammation. Here, we critically review the relationship between αS and microglial activation depending on its aggregation state and its role in neuroinflammation to explore the potential of TNFα inhibitors as a treatment strategy for MSA and other neurodegenerative diseases. BioMed Central 2019-04-11 /pmc/articles/PMC6458780/ /pubmed/30975183 http://dx.doi.org/10.1186/s12974-019-1477-5 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Ndayisaba, Alain
Jellinger, Kurt
Berger, Thomas
Wenning, Gregor K.
TNFα inhibitors as targets for protective therapies in MSA: a viewpoint
title TNFα inhibitors as targets for protective therapies in MSA: a viewpoint
title_full TNFα inhibitors as targets for protective therapies in MSA: a viewpoint
title_fullStr TNFα inhibitors as targets for protective therapies in MSA: a viewpoint
title_full_unstemmed TNFα inhibitors as targets for protective therapies in MSA: a viewpoint
title_short TNFα inhibitors as targets for protective therapies in MSA: a viewpoint
title_sort tnfα inhibitors as targets for protective therapies in msa: a viewpoint
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458780/
https://www.ncbi.nlm.nih.gov/pubmed/30975183
http://dx.doi.org/10.1186/s12974-019-1477-5
work_keys_str_mv AT ndayisabaalain tnfainhibitorsastargetsforprotectivetherapiesinmsaaviewpoint
AT jellingerkurt tnfainhibitorsastargetsforprotectivetherapiesinmsaaviewpoint
AT bergerthomas tnfainhibitorsastargetsforprotectivetherapiesinmsaaviewpoint
AT wenninggregork tnfainhibitorsastargetsforprotectivetherapiesinmsaaviewpoint

Ejemplares similares